Correction to: Efficacy and safety of ropeginterferon alfa-2b in Japanese patients with polycythemia vera: an open-label, single-arm, phase 2 study (International Journal of Hematology, (2022), 116, 2, (215-227), 10.1007/s12185-022-03341-9)

Yoko Edahiro; Kohshi Ohishi; Akihiko Gotoh; Katsuto Takenaka; Hirohiko Shibayama; Takayuki Shimizu; Kensuke Usuki; Kazuya Shimoda; Masafumi Ito; Scott A. VanWart; Oleh Zagrijtschuk; Albert Qin; Hiroaki Kawase; Narihisa Miyachi; Toshiaki Sato; Norio Komatsu; Keita Kirito

doi:10.1007/s12185-022-03440-7

Correction to: Efficacy and safety of ropeginterferon alfa-2b in Japanese patients with polycythemia vera: an open-label, single-arm, phase 2 study (International Journal of Hematology, (2022), 116, 2, (215-227), 10.1007/s12185-022-03341-9)

Yoko Edahiro, Kohshi Ohishi, Akihiko Gotoh, Katsuto Takenaka, Hirohiko Shibayama, Takayuki Shimizu, Kensuke Usuki, Kazuya Shimoda, Masafumi Ito, Scott A. VanWart, Oleh Zagrijtschuk, Albert Qin, Hiroaki Kawase, Narihisa Miyachi, Toshiaki Sato, Norio Komatsu, Keita Kirito

Department of Internal Medicine (Hematology)

Research output: Contribution to journal › Comment/debate › peer-review

Abstract

In the original publication of the article, in Table 3 [Summary of adverse events (safety population)], the number of patients who developed suicidal ideation related to study drug (n = 1) was erroneously described, and the correct number is 0 (zero). Therefore, the number of patients who developed psychiatric disorders has also been revised from 2 (6.9) to 1 (3.4). The correct Table 3 is given in this correction.

Original language	English
Pages (from-to)	642-643
Number of pages	2
Journal	International journal of hematology
Volume	116
Issue number	4
DOIs	https://doi.org/10.1007/s12185-022-03440-7
Publication status	Published - 2022 Oct

ASJC Scopus subject areas

Hematology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1007/s12185-022-03440-7

Fingerprint

Dive into the research topics of 'Correction to: Efficacy and safety of ropeginterferon alfa-2b in Japanese patients with polycythemia vera: an open-label, single-arm, phase 2 study (International Journal of Hematology, (2022), 116, 2, (215-227), 10.1007/s12185-022-03341-9)'. Together they form a unique fingerprint.

Cite this

Edahiro, Y., Ohishi, K., Gotoh, A., Takenaka, K., Shibayama, H., Shimizu, T., Usuki, K., Shimoda, K., Ito, M., VanWart, S. A., Zagrijtschuk, O., Qin, A., Kawase, H., Miyachi, N., Sato, T., Komatsu, N., & Kirito, K. (2022). Correction to: Efficacy and safety of ropeginterferon alfa-2b in Japanese patients with polycythemia vera: an open-label, single-arm, phase 2 study (International Journal of Hematology, (2022), 116, 2, (215-227), 10.1007/s12185-022-03341-9). International journal of hematology, 116(4), 642-643. https://doi.org/10.1007/s12185-022-03440-7

Correction to: Efficacy and safety of ropeginterferon alfa-2b in Japanese patients with polycythemia vera: an open-label, single-arm, phase 2 study (International Journal of Hematology, (2022), 116, 2, (215-227), 10.1007/s12185-022-03341-9). / Edahiro, Yoko; Ohishi, Kohshi; Gotoh, Akihiko et al.
In: International journal of hematology, Vol. 116, No. 4, 10.2022, p. 642-643.

Research output: Contribution to journal › Comment/debate › peer-review

Edahiro, Y, Ohishi, K, Gotoh, A, Takenaka, K, Shibayama, H, Shimizu, T, Usuki, K, Shimoda, K, Ito, M, VanWart, SA, Zagrijtschuk, O, Qin, A, Kawase, H, Miyachi, N, Sato, T, Komatsu, N & Kirito, K 2022, 'Correction to: Efficacy and safety of ropeginterferon alfa-2b in Japanese patients with polycythemia vera: an open-label, single-arm, phase 2 study (International Journal of Hematology, (2022), 116, 2, (215-227), 10.1007/s12185-022-03341-9)', International journal of hematology, vol. 116, no. 4, pp. 642-643. https://doi.org/10.1007/s12185-022-03440-7

Edahiro Y, Ohishi K, Gotoh A, Takenaka K, Shibayama H, Shimizu T et al. Correction to: Efficacy and safety of ropeginterferon alfa-2b in Japanese patients with polycythemia vera: an open-label, single-arm, phase 2 study (International Journal of Hematology, (2022), 116, 2, (215-227), 10.1007/s12185-022-03341-9). International journal of hematology. 2022 Oct;116(4):642-643. doi: 10.1007/s12185-022-03440-7

Edahiro, Yoko ; Ohishi, Kohshi ; Gotoh, Akihiko et al. / Correction to : Efficacy and safety of ropeginterferon alfa-2b in Japanese patients with polycythemia vera: an open-label, single-arm, phase 2 study (International Journal of Hematology, (2022), 116, 2, (215-227), 10.1007/s12185-022-03341-9). In: International journal of hematology. 2022 ; Vol. 116, No. 4. pp. 642-643.

@article{c1ac0a7d61214c7fb9c869236025a3d7,

title = "Correction to: Efficacy and safety of ropeginterferon alfa-2b in Japanese patients with polycythemia vera: an open-label, single-arm, phase 2 study (International Journal of Hematology, (2022), 116, 2, (215-227), 10.1007/s12185-022-03341-9)",

abstract = "In the original publication of the article, in Table 3 [Summary of adverse events (safety population)], the number of patients who developed suicidal ideation related to study drug (n = 1) was erroneously described, and the correct number is 0 (zero). Therefore, the number of patients who developed psychiatric disorders has also been revised from 2 (6.9) to 1 (3.4). The correct Table 3 is given in this correction.",

author = "Yoko Edahiro and Kohshi Ohishi and Akihiko Gotoh and Katsuto Takenaka and Hirohiko Shibayama and Takayuki Shimizu and Kensuke Usuki and Kazuya Shimoda and Masafumi Ito and VanWart, {Scott A.} and Oleh Zagrijtschuk and Albert Qin and Hiroaki Kawase and Narihisa Miyachi and Toshiaki Sato and Norio Komatsu and Keita Kirito",

note = "Publisher Copyright: {\textcopyright} Japanese Society of Hematology 2022.",

year = "2022",

month = oct,

doi = "10.1007/s12185-022-03440-7",

language = "English",

volume = "116",

pages = "642--643",

journal = "International journal of hematology",

issn = "0925-5710",

publisher = "Springer Japan",

number = "4",

}

TY - JOUR

T1 - Correction to

T2 - Efficacy and safety of ropeginterferon alfa-2b in Japanese patients with polycythemia vera: an open-label, single-arm, phase 2 study (International Journal of Hematology, (2022), 116, 2, (215-227), 10.1007/s12185-022-03341-9)

AU - Edahiro, Yoko

AU - Ohishi, Kohshi

AU - Gotoh, Akihiko

AU - Takenaka, Katsuto

AU - Shibayama, Hirohiko

AU - Shimizu, Takayuki

AU - Usuki, Kensuke

AU - Shimoda, Kazuya

AU - Ito, Masafumi

AU - VanWart, Scott A.

AU - Zagrijtschuk, Oleh

AU - Qin, Albert

AU - Kawase, Hiroaki

AU - Miyachi, Narihisa

AU - Sato, Toshiaki

AU - Komatsu, Norio

AU - Kirito, Keita

PY - 2022/10

Y1 - 2022/10

N2 - In the original publication of the article, in Table 3 [Summary of adverse events (safety population)], the number of patients who developed suicidal ideation related to study drug (n = 1) was erroneously described, and the correct number is 0 (zero). Therefore, the number of patients who developed psychiatric disorders has also been revised from 2 (6.9) to 1 (3.4). The correct Table 3 is given in this correction.

AB - In the original publication of the article, in Table 3 [Summary of adverse events (safety population)], the number of patients who developed suicidal ideation related to study drug (n = 1) was erroneously described, and the correct number is 0 (zero). Therefore, the number of patients who developed psychiatric disorders has also been revised from 2 (6.9) to 1 (3.4). The correct Table 3 is given in this correction.

UR - http://www.scopus.com/inward/record.url?scp=85136688058&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85136688058&partnerID=8YFLogxK

U2 - 10.1007/s12185-022-03440-7

DO - 10.1007/s12185-022-03440-7

M3 - Comment/debate

C2 - 36029457

AN - SCOPUS:85136688058

SN - 0925-5710

VL - 116

SP - 642

EP - 643

JO - International journal of hematology

JF - International journal of hematology

IS - 4

ER -

Correction to: Efficacy and safety of ropeginterferon alfa-2b in Japanese patients with polycythemia vera: an open-label, single-arm, phase 2 study (International Journal of Hematology, (2022), 116, 2, (215-227), 10.1007/s12185-022-03341-9)

Abstract

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this